Sherrif, Bioshares is a subscription magazine and as such is copyright. It would be improper and probably unlawful for me to post directly from it. As a subscription magazine, you cannot access it unless you subscribe. Not much in the article would be news to anyone who has read all the info put out by the Company. My summary of the important bits follows: They emphasised the importance of IL-6. If the FDA considers IL-6 a surrogate bio-marker for SLE this can speed up clinical development enormously. They emphasise that SLE is an unmet need. The opportunity to quickly ascertain the potential of INV103 (XToll) as a treatment for SLE adds considerable value to the Invion investment potential. Bioshares has a Speculative Buy Class A for this stock. This is a rare classification for this magazine. I truly believe that this stock is a wealth creator. I know it has a bad track record but this is a new company with competent, honest, experienced management and it should not have to carry the baggage from the past. Neglect it at your peril
IVX Price at posting:
6.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)